The Protective Effect of Low Dose of Lipopolysaccharide Pretreatment on Endotoxin-Induced Uveitis in Rats Is Associated with Downregulation of CSF-1 and Upregulation of LRR-1.
Animals
Cytokines
/ metabolism
Disease Models, Animal
Down-Regulation
Endotoxins
/ metabolism
Humans
Inflammation Mediators
/ metabolism
Intracellular Signaling Peptides and Proteins
/ metabolism
Lipopolysaccharides
/ therapeutic use
Macrophage Colony-Stimulating Factor
/ genetics
Male
Rats
Rats, Wistar
Repressor Proteins
/ genetics
Signal Transduction
Up-Regulation
Uveitis
/ therapy
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
12
2019
revised:
26
05
2020
accepted:
05
06
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
22
5
2021
Statut:
epublish
Résumé
To observe the effect of low dose of lipopolysaccharide (LPS) pretreatment on the expression of CSF-1 and LRR-1 in rats with endotoxin-induced uveitis (EIU), and to explore the possible role of TLR4. EIU was induced by a single subcutaneous injection of 200 : Low dose of LPS pretreatment produced a suppressive effect by significantly reducing the inflammatory reaction of anterior segment as measured by slit lamp and histopathology. It also significantly reduced the concentrations of IL-17, INF- Low dose of LPS pretreatment can ameliorate endotoxin-induced uveitis in rats. This protection may be associated with upregulation of LRR-1 and downregulation of CSF-1, which is regulated by TLR4 signaling pathway.
Identifiants
pubmed: 32671118
doi: 10.1155/2020/9314756
pmc: PMC7350171
doi:
Substances chimiques
Cytokines
0
Endotoxins
0
Inflammation Mediators
0
Intracellular Signaling Peptides and Proteins
0
Lipopolysaccharides
0
Lrr1 protein, rat
0
Repressor Proteins
0
Macrophage Colony-Stimulating Factor
81627-83-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9314756Informations de copyright
Copyright © 2020 Yunli Ling et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4631-8
pubmed: 20616063
Curr Mol Med. 2015;15(6):543-9
pubmed: 26238370
J Cell Mol Med. 2020 Mar;24(5):3128-3138
pubmed: 31994318
Br J Pharmacol. 1999 Sep;128(1):5-12
pubmed: 10498828
Int J Mol Sci. 2012;13(6):7508-20
pubmed: 22837708
Am J Pathol. 2008 Nov;173(5):1440-54
pubmed: 18832572
Invest Ophthalmol Vis Sci. 1991 Jan;32(1):88-95
pubmed: 1987109
Vet Immunol Immunopathol. 2016 Oct 15;179:70-6
pubmed: 27590428
Vestn Oftalmol. 2017;133(1):27-31
pubmed: 28291196
Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1557-61
pubmed: 16565392
Ocul Immunol Inflamm. 2019 Nov 25;:1-8
pubmed: 31763950
Postgrad Med J. 2017 Dec;93(1106):766-773
pubmed: 28942431
Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3278-88
pubmed: 7519183
Mol Vis. 2011 Jan 18;17:170-6
pubmed: 21264236
Methods Mol Biol. 2019;1960:161-168
pubmed: 30798530
Biomed Pharmacother. 2018 Jul;103:662-679
pubmed: 29679908
Mol Vis. 2010 Aug 21;16:1689-95
pubmed: 20806043
Crit Rev Immunol. 2015;35(4):293-323
pubmed: 26757393
J Immunol Res. 2017;2017:1273940
pubmed: 28804726
Indian J Ophthalmol. 2016 Sep;64(9):628-634
pubmed: 27853008
Autophagy. 2011 Sep;7(9):1082-4
pubmed: 21606681
Ocul Immunol Inflamm. 2018;26(6):943-950
pubmed: 28609207
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5450-7
pubmed: 18757518
Organogenesis. 2013 Oct 1;9(4):249-60
pubmed: 23974218
Mol Vis. 2009;15:619-28
pubmed: 19347047
Br J Ophthalmol. 2017 May;101(5):548-550
pubmed: 28100481
Mol Cells. 2001 Dec 31;12(3):304-12
pubmed: 11804328
J Cell Biochem. 2019 Jan;120(1):56-70
pubmed: 30246452
Mediators Inflamm. 2010;2010:748218
pubmed: 20847811
FEBS J. 2018 Feb;285(4):777-787
pubmed: 28834216
Clin Med Res. 2006 Dec;4(4):294-309
pubmed: 17210978